Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis

Exclusion Criteria15

• Secondary retroperitoneal fibrosis including drug-related retroperitoneal fibrosis, active infections (such as tuberculosis) or malignancies, systemic vasculitis (such as Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis), Erdheim-Chester disease (Appendix 17.3),patients with IgG4 disease may be enrolled
• Contraindication to perform FDG-PET/CT,
• Contraindication to perform CT scan with injection of contrast agent,
• Contraindication to treatment by prednisone
• Active infection
• Acute or chronic liver disease that is deemed sufficiently severe to impair their ability to participate in the trial,
• Active or history of malignancy in last 5 years. Individuals with squamous cell or basal cell skin carcinomas and individuals with cervical carcinoma in situ may be enrolled if they have received curative surgical treatment,
• Serum creatinine level greater than 400 µmol/L that cannot be attributed to underlying IRF,
• Live vaccination received from 4 weeks before inclusion,
• Inhaled glucocorticoids (except for patients with documented asthma),
• Any previous treatment with rituximab, methotrexate, alemtuzumab, cyclophosphamide, azathioprine, mycophenolate mofetil, infliximab, adalimumab, etanercept within the past 3 months,
• Pregnancy or breastfeeding,
• Non-affiliation to a social security regime,
• Subject deprived of freedom, subject under a legal protective measure
• Refusal to participate